title: [A clinico-laboratory assessment of the efficacy of dalargin in treating acute suppurative-inflammatory processes in the maxillofacial area].
abstract: Dalargin effects on the immune status parameters were studied in patients with acute pyoinflammatory processes of the soft tissues of the face. Tsen. lymphocyte subpopulation was found to be increasing in all the patients during therapy, whatever the clinical course of the underlying disease. Another finding was a significant elevation of the functional activity of the peripheral blood polymorphonuclear neutrophils. These data were confirmed in vitro when dalargin was added to a leukocyte suspension, though it was known to exert no bactericidal activity. These results permit recommending dalargin for the correction of the immunity status of patients with grave pyoinflammatory diseases of the soft maxillofacial tissues.
authors.forename: N N
authors.initials: NN
authors.lastname: Bazhanov
authors.forename: S S
authors.initials: SS
authors.lastname: Ganina
authors.forename: Ch R
authors.initials: ChR
authors.lastname: Ragimov
authors.forename: S B
authors.initials: SB
authors.lastname: Pashutin
authors.forename: L I
authors.initials: LI
authors.lastname: Brusina
mesh_terms: D000208:Acute Disease; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D002481:Cellulitis / Q000188:drug therapy* / Q000276:immunology; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D016308:Enkephalin, Leucine-2-Alanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005145:Face; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007571:Jaw Diseases / Q000188:drug therapy* / Q000276:immunology; D008297:Male
chemical_list: D000276:Adjuvants, Immunologic; D016308:Enkephalin, Leucine-2-Alanine; C040996:enkephalin-Leu, Ala(2)-Arg(6)-
vernacular_title: Kliniko-laboratornaia otsenka éffektivnosti dalargina pri lechenii ostrykh gnoĭno-vospalitel'nykh protsessov cheliustno-litsevoĭ oblasti.